Assess whether to resubmit, meet, or pause the program (2db223)

SITUATION After a literature paper the 505(b)(2) package leans on getting retracted, disproportionate reporting signal workbook is what labeling negotiator can touch in a 505(b)(2) program relying on literature plus a bridging study. Pharma & Life Sciences will live with To resubmit, meet, versus Pause the program on this CMC and Development Pathways file.

DECISION Labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study must choose To resubmit, meet, / Pause the program using disproportionate reporting signal workbook after a literature paper the 505(b)(2) package leans on getting retracted.

HYPOTHESES TO TEST 1. The population in disproportionate reporting signal workbook is the one a literature paper the 505(b)(2) package leans on getting retracted named, so To resubmit, meet, follows for this CMC and Development Pathways file. 2. The population in disproportionate reporting signal workbook is adjacent only to a literature paper the 505(b)(2) package leans on getting retracted; Pause the program is the honest Pharma & Life Sciences call. 3. A 505(b)(2) program relying on literature plus a bridging study already contained a literature paper the 505(b)(2) package leans on getting retracted before disproportionate reporting signal workbook arrived; no new CMC and Development Pathways path. 4. Provenance on disproportionate reporting signal workbook after a literature paper the 505(b)(2) package leans on getting retracted is broken; do not pick To resubmit, meet, or Pause the program yet.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 3. Check whether disproportionate reporting signal workbook supports the labeled claim labeling negotiator would keep. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read disproportionate reporting signal workbook against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move to resubmit, meet, or for labeling negotiator.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / CMC and Development Pathways packet (disproportionate reporting signal workbook after a literature paper the 505(b)(2) package leans on getting retracted). The follow-on CMC and Development Pathways action is what labeling negotiator does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in disproportionate reporting signal workbook, then the action for labeling negotiator - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - Named option among To resubmit, meet,, Pause the program and the fact that kills the others - Owner and next date for labeling negotiator in a 505(b)(2) program relying on literature plus a bridging study